The invention is concerned with novel biaryl derivatives of formula (I),
wherein
m, R1, R2, R3, X1, X2 and X3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.
N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS
申请人:F. Hoffmann-La Roche AG
公开号:EP2205583A2
公开(公告)日:2010-07-14
US8153805B2
申请人:——
公开号:US8153805B2
公开(公告)日:2012-04-10
[EN] NEW BIARYL DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE BIARYLE
申请人:HOFFMANN LA ROCHE
公开号:WO2009043747A2
公开(公告)日:2009-04-09
The invention is concerned with novel biaryl derivatives of Formula (I), wherein Formula (A), m, R1, R2, R3, X1, X2 and X3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.
NOVEL BIARYL DERIVATIVES
申请人:Aebi Johannes
公开号:US20090048238A1
公开(公告)日:2009-02-19
The invention is concerned with novel biaryl derivatives of formula (I),
wherein
m, R
1
, R
2
, R
3
, X
1
, X
2
and X
3
are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.